Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group-Reference-Cited by-同舟云学术

Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

Published:2022-01-17 Issue:2 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

del Alcázar Elena¹^ORCID,López‐Ferrer Anna²,Martínez‐Doménech Álvaro³^ORCID,Ruiz‐Villaverde Ricardo⁴^ORCID,Llamas‐Velasco Mª. del Mar⁵^ORCID,Rocamora Vicenç⁶,Julià Marc⁷,Notario Jaime⁸,Fernández‐Freire Lourdes Rodríguez⁹,Sahuquillo‐Torralba Antonio¹⁰,Vidal David¹¹,Rivera Raquel¹²^ORCID,Carretero Gregorio¹³,Mateu Almudena¹⁴,Cueva Pablo¹⁵,Carrascosa José Manuel¹^ORCID

Affiliation:

1. Department of Dermatology, Hospital Universitari Germans Trias i Pujol Universitat Autònoma de Barcelona (UAB) Badalona Spain

2. Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

3. Department of Dermatology Hospital General Universitario de Valencia Valencia Spain

4. Department of Dermatology Hospital Clínico Universitario San Cecilio Granada Spain

5. Department of Dermatology Hospital Universitario de la Princesa Madrid Spain

6. Department of Dermatology Hospital de Manacor (Illes Balears) Manacor Spain

7. Department of Dermatology Hospital Universitario de Basurto Bilbao Spain

8. Department of Dermatology Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat Barcelona Spain

9. Department of Dermatology Hospital Universitario Virgen del Rocío Sevilla Spain

10. Department of Dermatology Hospital Universitario y Politécnico La Fe Valencia, Instituto de Investigación Sanitaria La Fe Valencia Spain

11. Department of Dermatology Complex Hospitalari Moisès Broggi, Sant Joan Despí (Barcelona) Barcelona Spain

12. Department of Dermatology Hospital Universitario 12 de Octubre Madrid Spain

13. Department of Dermatology Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria Las Palmas Spain

14. Department of Dermatology Hospital Universitario Dr. Peset Valencia Spain

15. Department of Dermatology Hospital Infanta Leonor Madrid Spain

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15231

Reference27 articles.

1. European Medicine Agency.Tremfya (Guselkumab): summary of product characteristics.2019https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_es.pdf

2. New Insights in the Immunologic Basis of Psoriasis

3. The role of IL 23 in the treatment of psoriasis

4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

5. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of biologic treatment for psoriasis in Malaysia: Real-world evidence and review of current evidence from Southeast Asia;Dermatologica Sinica;2024-04

2. Real‐life data over 36 weeks of guselkumab treatment in psoriasis patients: A single‐center study from Turkey;Journal of Cosmetic Dermatology;2024-03-15

3. Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series;Skin Health and Disease;2023-09-19

4. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real‐world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group;Journal of the European Academy of Dermatology and Venereology;2023-09

5. Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study;Journal of the European Academy of Dermatology and Venereology;2023-08-24